Status:
COMPLETED
Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed Conditions
Lead Sponsor:
Mutah University
Conditions:
Pharmacokinetic Parameters
Eligibility:
All Genders
25-40 years
Phase:
NA
Brief Summary
Background: The current study is a randomized, open-label, two-period, two-sequence, two-way crossover pharmacokinetic study in healthy Jordanian subjects to evaluate the pharmacokinetics and bioequiv...
Eligibility Criteria
Inclusion
- healthy
- Jordanian volunteers
- some private hospitals (Amman, Jordan) Phase I Clinical Unit
Exclusion
- Smokers
- heavy drinkers
- those who used CYP enzyme inhibitors within the previous 60 days
- those who had taken any medicine within the previous four weeks
- those who had a history of medication allergies
- those who had participated in previous clinical studies within the previous six months
- those with any significant clinical abnormality
Key Trial Info
Start Date :
May 17 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 12 2021
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT05229796
Start Date
May 17 2021
End Date
December 12 2021
Last Update
February 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wael Abu Dayyih
Amman, None Selected, Jordan, 11196